Published in AJR Am J Roentgenol on July 01, 2010
ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol (2015) 1.03
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI. Eur Radiol (2012) 0.96
Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol (2011) 0.96
Contrast-enhanced free-breathing 3D T1-weighted gradient-echo sequence for hepatobiliary MRI in patients with breath-holding difficulties. Eur Radiol (2013) 0.95
Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Imaging (2012) 0.92
Hepatic pathology after Fontan palliation: spectrum of imaging findings. Pediatr Radiol (2012) 0.92
Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver (2011) 0.92
Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem (2013) 0.88
Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol (2015) 0.85
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther (2016) 0.84
Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients. Radiother Oncol (2015) 0.83
The role of MRI using liver-specific contrast agent in the assessment of focal liver lesion. Radiol Bras (2015) 0.82
Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI--typical, atypical, pre- and post-treatment evaluation. Pediatr Radiol (2012) 0.81
Imaging-based evaluation of liver function: comparison of ⁹⁹mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol (2014) 0.81
Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography. World J Gastroenterol (2012) 0.80
Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol (2011) 0.80
The impact of hepatocyte phase imaging from infancy to young adulthood in patients with a known or suspected liver lesion. Pediatr Radiol (2014) 0.80
Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol (2015) 0.80
Imaging of malignancies of the biliary tract- an update. Cancer Imaging (2014) 0.79
Imaging of HCC-Current State of the Art. Diagnostics (Basel) (2015) 0.79
Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children. Pediatr Radiol (2014) 0.79
Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI. Acad Radiol (2014) 0.78
Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver. Korean J Radiol (2015) 0.78
State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am (2016) 0.78
Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma. Eur Radiol (2014) 0.78
Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol (2015) 0.78
Recent advances in the imaging of hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.77
Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol (2014) 0.77
Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol (2015) 0.77
Non-invasive diagnosis of abdomino-pelvic masses: role of multimodality imaging. J Clin Imaging Sci (2013) 0.76
Two- versus three-dimensional dual gradient-echo MRI of the liver: a technical comparison. Eur Radiol (2012) 0.76
Targeted MRI contrast agents for pediatric hepatobiliary disease. J Pediatr Gastroenterol Nutr (2012) 0.76
Validation of 10-Minute Delayed Hepatocyte Phase Imaging with 30° Flip Angle in Gadoxetic Acid-Enhanced MRI for the Detection of Liver Metastasis. PLoS One (2015) 0.76
Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients. Acta Radiol (2015) 0.75
Quantitative Assessment of Liver Function Using Gadoxetate-Enhanced Magnetic Resonance Imaging: Monitoring Transporter-Mediated Processes in Healthy Volunteers. Invest Radiol (2017) 0.75
Unexpected uptake of gadoxetic acid in a hepatic metastasis from T-cell lymphoma. Cancer Imaging (2012) 0.75
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid. World J Gastroenterol (2016) 0.75
Gadoxetate Disodium enhanced spectral dual-energy CT for evaluation of cholangiocarcinoma: Preliminary data. Ann Med Surg (Lond) (2016) 0.75
Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. Acta Radiol Open (2015) 0.75
Systemic treatment in breast cancer: a primer for radiologists. Insights Imaging (2015) 0.75
Adult living donor liver imaging. Diagn Interv Radiol (2016) 0.75
Safety and Efficacy of Gadoxetate Disodium-Enhanced Liver MRI in Pediatric Patients Aged >2 Months to <18 Years-Results of a Retrospective, Multicenter Study. Magn Reson Insights (2016) 0.75
Combining hyperpolarized (13) C MRI with a liver-specific gadolinium contrast agent for selective assessment of hepatocyte metabolism. Magn Reson Med (2016) 0.75
MRI of paediatric liver tumours: How we review and report. Cancer Imaging (2016) 0.75
Transient washout of hepatic hemangiomas: Potential pitfall mimicking malignancy. Radiol Case Rep (2016) 0.75
Gd-EOB-DTPA-Enhanced MR Imaging of the Liver: The Effect on T2 Relaxation Times and Apparent Diffusion Coefficient (ADC). Pol J Radiol (2016) 0.75
ECR 2012 Book of Abstracts - Disclosures. Insights Imaging (2012) 0.75
Two cases of near-complete regression of focal nodular hyperplasia of the liver: Case reports and review of the literature. Radiol Case Rep (2015) 0.75
Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents--comparison of Gd-EOB-DTPA and Gd-BOPTA. BMC Med Imaging (2013) 0.75
Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Res (2016) 0.75
Gaucher disease in the liver on hepatocyte specific contrast agent enhanced MR imaging. Pediatr Radiol (2017) 0.75
Quantitative evaluation of Gd-EOB-DTPA uptake in focal liver lesions by using T1 mapping: differences between hepatocellular carcinoma, hepatic focal nodular hyperplasia and cavernous hemangioma. Oncotarget (2017) 0.75
Magnetic resonance imaging of primary pediatric liver tumors. Pediatr Radiol (2016) 0.75
Intravoxel Incoherent Motion Diffusion-weighted Imaging: Evaluation of the Differentiation of Solid Hepatic Lesions. Transl Oncol (2017) 0.75
Review of internal hernias: radiographic and clinical findings. AJR Am J Roentgenol (2006) 5.32
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol (2007) 3.17
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
In vivo characterization of the liver fat ¹H MR spectrum. NMR Biomed (2010) 3.07
Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging (2011) 2.75
Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res (2009) 2.63
Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions. Radiology (2012) 2.51
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. Radiographics (2005) 2.37
T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging (2011) 2.27
Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology (2006) 2.23
Fatty liver: imaging patterns and pitfalls. Radiographics (2006) 2.21
Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging (2009) 2.18
Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magn Reson Imaging (2011) 2.15
Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology (2005) 2.14
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Abdominal wall hernias: imaging features, complications, and diagnostic pitfalls at multi-detector row CT. Radiographics (2005) 1.98
Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging (2012) 1.90
Renal stone assessment with dual-energy multidetector CT and advanced postprocessing techniques: improved characterization of renal stone composition--pilot study. Radiology (2009) 1.90
Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol (2006) 1.87
SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology (2010) 1.81
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Endovascular treatment of visceral artery aneurysms. J Endovasc Ther (2002) 1.75
Towards task-based assessment of CT performance: system and object MTF across different reconstruction algorithms. Med Phys (2012) 1.72
Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med (2011) 1.67
Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging (2011) 1.66
MR imaging of liver fibrosis: current state of the art. Radiographics (2009) 1.62
Disproportionate fat stranding: a helpful CT sign in patients with acute abdominal pain. Radiographics (2004) 1.54
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Optimal phased-array combination for spectroscopy. Magn Reson Imaging (2008) 1.48
Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol (2008) 1.47
Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics (2009) 1.46
Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol (2007) 1.42
Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology (2008) 1.41
Challenges in screening for hepatocellular carcinoma in the glycogen storage disease type 1a population. Intern Med (2012) 1.38
Cross-sectional imaging of extranodal involvement in abdominopelvic lymphoproliferative malignancies. Radiographics (2007) 1.38
A review of MR physics: 3T versus 1.5T. Magn Reson Imaging Clin N Am (2007) 1.37
Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol (2008) 1.36
Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol (2010) 1.33
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology (2014) 1.33
LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology (2014) 1.31
High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology (2007) 1.22
CT appearance of the normal appendix in adults. Eur Radiol (2005) 1.21
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (2015) 1.18
Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol (2010) 1.17
Cisterna chyli at routine abdominal MR imaging: a normal anatomic structure in the retrocrural space. Radiographics (2004) 1.11
Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol (2012) 1.11
Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics (2008) 1.10
Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr (2010) 1.08
Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging (2012) 1.08
Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol (2013) 1.08
Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol (2011) 1.04
Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging (2012) 1.03
MR contrast agents for liver imaging: what, when, how. Radiographics (2006) 1.03
Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology (2014) 1.02
Low-flow vascular malformations: MR-guided percutaneous sclerotherapy in qualitative and quantitative assessment of therapy and outcome. Radiology (2004) 1.02
Constraining the initial phase in water-fat separation. Magn Reson Imaging (2010) 1.02
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Robustness of fat quantification using chemical shift imaging. Magn Reson Imaging (2011) 0.99
Time-resolved MR angiography as a useful sequence for assessment of ovarian vein reflux. AJR Am J Roentgenol (2009) 0.98
Calcified vascular plaque specimens: assessment with cardiac dual-energy multidetector CT in anthropomorphically moving heart phantom. Radiology (2008) 0.97
Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol (2007) 0.97
Pulmonary hypertrophic osteoarthropathy in a patient with nonsmall cell lung cancer: Diagnosis with FDG PET/CT. Clin Nucl Med (2006) 0.96
Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging. J Magn Reson Imaging (2008) 0.95
Hypotensive patients with blunt abdominal trauma: performance of screening US. Radiology (2005) 0.95
Multislice helical CT of the pancreas and spleen. Eur J Radiol (2003) 0.95
Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. J Magn Reson Imaging (2013) 0.94
Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging (2014) 0.94
Focal cystic high-attenuation lesions: characterization in renal phantom by using photon-counting spectral CT--improved differentiation of lesion composition. Radiology (2010) 0.94
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging (2013) 0.94
MRI of the pelvis in women: 3D versus 2D T2-weighted technique. AJR Am J Roentgenol (2010) 0.94
Hepatobiliary agents and their role in LI-RADS. Abdom Imaging (2015) 0.93
Central veins of the chest: evaluation with time-resolved MR angiography. Radiology (2008) 0.93
Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics (2011) 0.93
N/2 ghosting artifacts: elimination at 3.0-T MR cholangiography with SPACE pulse sequence. Radiology (2008) 0.93
Coronary stent patency: dual-energy multidetector CT assessment in a pilot study with anthropomorphic phantom. Radiology (2008) 0.93
Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging (2011) 0.92
Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Imaging (2012) 0.92
Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know. Adv Anat Pathol (2015) 0.92
Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. Eur Radiol (2003) 0.91
Cardiac motion in diffusion-weighted MRI of the liver: artifact and a method of correction. J Magn Reson Imaging (2011) 0.91
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.91
Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol (2010) 0.91
Chest radiography with a flat-panel detector: image quality with dose reduction after copper filtration. Radiology (2005) 0.90
A quantitative approach to sequence and image weighting. J Comput Assist Tomogr (2010) 0.90
Improvement in B1-inhomogeneity artifacts in the abdomen at 3T MR imaging using a radiofrequency cushion. J Magn Reson Imaging (2008) 0.90
Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging (2011) 0.89
Multi-detector row CT of the small bowel: peak enhancement temporal window--initial experience. Radiology (2007) 0.89
Abdominal magnetic resonance imaging at 3.0 T what is the ultimate gain in signal-to-noise ratio? Acad Radiol (2006) 0.88
High-pitch coronary CT angiography with third generation dual-source CT: limits of heart rate. Int J Cardiovasc Imaging (2014) 0.88
Cross-sectional investigation of correlation between hepatic steatosis and IVIM perfusion on MR imaging. Magn Reson Imaging (2012) 0.88
Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2012) 0.88
Imaging features of perivascular fatty infiltration of the liver: initial observations. Radiology (2005) 0.87
Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. Fertil Steril (2005) 0.87